
To recommend strategies to bridge therapy with zzso zzso zzso in obese patients and in patients with zzso zzso 

A zzso search was performed of the literature from January zzso zzso Published material dealing with bridging of zzso therapy or short-term use of zzso therapy in patients with zzso dysfunction or obesity was zzso The manufacturers of zzso zzso and zzso were contacted for the references used to determine dosing zzso 

Although zzso has been commonly used to bridge therapy, our search revealed no trials that specifically examined zzso bridge therapy in obese patients or in patients with zzso zzso However, nine trials using zzso in obese patients and 14 trials using zzso in patients with zzso dysfunction were zzso When compared with zzso individuals, obese patients receiving zzso and zzso based on total body weight did not demonstrate higher zzso rates or zzso zzso zzso zzso zzso zzso levels were more common with zzso dosing of zzso than with dosing every 12 zzso zzso accumulates in patients with a zzso clearance of 30 zzso or less; in this population, zzso dosage adjustments have been zzso zzso does not accumulate in patients with a zzso clearance of 20 zzso or greater after at least 10 days of zzso 

zzso patients, weighing zzso zzso receiving zzso for bridge therapy should receive zzso based on total body zzso zzso zzso is recommended in patients weighing more than 150 zzso however, if zzso is used, zzso zzso levels should be zzso zzso with zzso should be limited to patients with a zzso clearance greater than 30 zzso The use of zzso 1 zzso zzso for patients with a zzso clearance of 30 zzso or less is not recommended for zzso bridge zzso zzso may be considered for zzso of high-risk patients with recent or zzso zzso zzso who have a zzso clearance of at least 20 zzso 

